ELN

Across TCGA pan-cancer cohorts, ELN mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ELN data layer compared with 28 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ELN mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ELN expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

LUAD, PDAC, and HNSC are the cancer types where ELN mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	II,III,IV	0.564	0.991	.003	22	view →
PDAC	DFS	Median	III,IV	0.862	0.564	.002	20	view →
HNSC	OS	Quartile	II,III,IV	0.907	1.000	.013	12	view →
LSCC	DFS	Median	All	0.991	0.560	.016	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ELN–LUAD (DFS)

Open the LUAD breakdown →